Key Insights

Highlights

Treatment Research

4 treatments under study, led by Avelumab

Research Leaders

5 sponsors active, led by Bayer

Related Conditions

Often studied with 6 related conditions

Clinical Risk Assessment

Based on trial outcomes

High Risk

Score: 100/100

Termination Rate

50.0%

1 terminated out of 2 trials

Success Rate

0.0%

-86.6% vs benchmark

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed with results

Key Signals

0

Data Visualizations

Phase Distribution

2Total
Phase 1 (2)

Trial Status

Recruiting1
Terminated1

Clinical Trials (2)

Showing 2 of 2 trials
NCT06217822Phase 1RecruitingPrimary

First-in-human Study of 225Ac-PSMA-Trillium (BAY 3563254) in Participants With Advanced Metastatic Castration-resistant Prostate Cancer (mCRPC)

NCT03861403Phase 1Terminated

A Dose Escalation and Expansion Study of TRX518 in Combination With Cyclophosphamide Plus Avelumab in Advanced Solid Tumors

Showing all 2 trials

Research Network

Common Treatments

  • Avelumab1
  • Trx5181
  • Cyclophosphamide1
  • 225acpsmatrillium Bay35632541

Active Sponsors

  • Bayer1
  • Bayer Consumer Care AG1
  • Pfizer1
  • Leap Therapeutics, Inc.1
  • Merck KGaA, Darmstadt, Germany1

Related Conditions

  • Solid Tumors1
  • Advanced Metastatic Castrationresistant Prostate Cancer With Prostate Specific Membrane Antigen Psma Expression1
  • Advanced Triple Negative Breast Cancer1
  • Advanced Platinumresistant Ovarian Cancer1
  • Prostate Specific Membrane Antigen Psma Expression1

Activity Timeline